Investor Presentaiton

Significant milestones achieved over last financial year FY2021/22 has been an extraordinary year where Clarity achieved several transformational milestones and advanced the clinical development of our TCT • • • · • 26 May 22 - Dr Neal Shore joins Clarity's Clinical Advisory Board 21 April 2022 - First patient treated in the US-based prostate cancer imaging trial of Cu-64 SAR-bisPSMA 5 April 2022 - Dr Andrei lagaru joins Clarity's Scientific Advisory Board 28 March 2022 - US-based Cu-64 SAR-bisPSMA trial in prostate cancer opens for recruitment 24 March 2022 - New clinical trial collaboration for Cu-64 SAR-bisPSMA in prostate cancer 25 February 2022 - First patient treated in cohort 2 SARTATE™M neuroblastoma therapy trial 7 February 2022 - US FDA Study May Proceed letter for Clarity's Cu-64 SAR-bisPSMA trial in prostate cancer 1 February 2022 - Clarity advances to cohort 2 in the SARTATE™M neuroblastoma trial • • • • • . 2 December 2021 - Clarity and Cardinal Health enter into Agreement for Targeted Copper Theranostics 1 December 2021 - Fifty percent recruitment milestone for PROPELLER prostate cancer trial 26 November 2021 - Clarity strengthens patent protection of SAR-bisPSMA 10 November 2021 - Recruitment for the dosimetry phase of Clarity's Cu-64/Cu-67 SAR-bisPSMA theranostic prostate cancer trial completed 19 October 2021 - Recruitment on C-BOBCAT pilot cancer trial closed for Clarity's SAR-Bombesin product 30 September 2021 - Clarity and Evergreen enter Targeted Copper Theranostics manufacturing agreement for US clinical trials 25 August 2021 - Clarity Pharmaceuticals lists on the ASX 25 August 2021 - First patient treated in Clarity's Cu-64/Cu-67 SAR-bisPSMA theranostic prostate cancer trial 10 August 2021 - First patient treated in Clarity's Cu-64 SAR- bisPSMA prostate cancer trial CLARITY 2014 MEIE 27

View entire presentation